Hologic, Inc. (NASDAQ:HOLX) Given Consensus Recommendation of “Hold” by Analysts

Shares of Hologic, Inc. (NASDAQ:HOLX) have earned a consensus recommendation of “Hold” from the fifteen analysts that are covering the stock, Marketbeat Ratings reports. Thirteen analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 12 month price target among analysts that have covered the stock in the last year is $78.4167.

HOLX has been the topic of a number of research analyst reports. Weiss Ratings reiterated a “hold (c)” rating on shares of Hologic in a research note on Wednesday, January 28th. BNP Paribas Exane cut shares of Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 price target on the stock. in a research report on Friday, November 21st. Evercore downgraded Hologic from an “outperform” rating to an “in-line” rating and decreased their price target for the stock from $79.00 to $78.00 in a research note on Monday, January 5th. Needham & Company LLC restated a “hold” rating on shares of Hologic in a research note on Tuesday, November 4th. Finally, Argus downgraded Hologic from a “buy” rating to a “hold” rating in a report on Monday, January 12th.

Hologic Stock Down 0.1%

Shares of NASDAQ HOLX opened at $75.14 on Friday. Hologic has a 1 year low of $51.90 and a 1 year high of $75.36. The stock’s 50-day simple moving average is $74.91 and its 200-day simple moving average is $71.80. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.32 and a current ratio of 4.04. The firm has a market cap of $16.77 billion, a price-to-earnings ratio of 31.31, a PEG ratio of 2.24 and a beta of 0.72.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.09 by ($0.05). The business had revenue of $1.05 billion for the quarter, compared to analysts’ expectations of $1.07 billion. Hologic had a return on equity of 19.58% and a net margin of 13.18%.Hologic’s revenue for the quarter was up 2.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.87 earnings per share. As a group, equities analysts anticipate that Hologic will post 4.28 earnings per share for the current fiscal year.

Institutional Trading of Hologic

Several institutional investors have recently added to or reduced their stakes in the business. Winnow Wealth LLC bought a new position in shares of Hologic in the 3rd quarter worth about $26,000. Caitong International Asset Management Co. Ltd raised its stake in Hologic by 193.6% during the second quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 273 shares during the period. Root Financial Partners LLC bought a new position in Hologic in the third quarter worth about $27,000. Harbor Capital Advisors Inc. bought a new position in Hologic in the fourth quarter worth about $27,000. Finally, SJS Investment Consulting Inc. boosted its stake in Hologic by 341.5% in the third quarter. SJS Investment Consulting Inc. now owns 468 shares of the medical equipment provider’s stock valued at $32,000 after acquiring an additional 362 shares during the period. Institutional investors own 94.73% of the company’s stock.

About Hologic

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.